Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2025; 17(9): 109035
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.109035
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.109035
From gut to liver: Exploring the relationship between inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease
Marina Amorim Lopes, Ellen Cristina Souza Oliveira, Leticia Evelyn Rocha Mendes, Julio Pinheiro Baima, Amanda Luísa Spiller, Ligia Yukie Sassaki, Department of Internal Medicine, Medical School, São Paulo State University (UNESP), Botucatu 18618-687, São Paulo, Brazil
Ana Elisa Valencise Quaglio, Verum Ingredients, Botucatu Technology Park, Botucatu 18605-525, São Paulo, Brazil
Andrey Santos, Department of Internal Medicine, School of Medical Sciences, University of Campinas (UNICAMP), Campinas 13083-887, São Paulo, Brazil
Marcello Imbrizi, Daniéla Oliveira Magro, Division of Gastroenterology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas 13083-970, São Paulo, Brazil
Rodrigo Fedatto Beraldo, Faculdade de Medicina, Fundação Dracenense de Educação e Cultura (FUNDEC), Dracena 17910-106, São Paulo, Brazil
Author contributions: Lopes MA, Oliveira ECS, Quaglio AEV, Santos A, Imbrizi M, Mendes LER, Beraldo RF, Baima JP, Spiller AL, Magro DO and Sassaki LY contributed equally to the conception and design of the article, writing, and editing of the manuscript, and review of the literature; all the authors approved the final version of the article to be published.
Supported by The São Paulo Research Foundation (FAPESP), Brazil, No. 2022/15527-3; The Postdoctoral Scholarship Grant from Medical School, São Paulo State University, No. PROPG/PROPE N° 06/2024; The Master Scholarship Grant from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil (CAPES)-Programa de Excelência Acadêmica (PROEX), No. 88887.807663/2023-00.
Conflict-of-interest statement: The authors have no conflict of interest to declare.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ligia Yukie Sassaki, MD, PhD, Assistant Professor, Researcher, Department of Internal Medicine, Medical School, São Paulo State University (UNESP), Av. Prof. Montenegro-Distrito de, Botucatu-SP, Botucatu 18618-687, São Paulo, Brazil.
Received: April 28, 2025
Revised: June 2, 2025
Accepted: August 20, 2025
Published online: September 27, 2025
Processing time: 150 Days and 14.3 Hours
Revised: June 2, 2025
Accepted: August 20, 2025
Published online: September 27, 2025
Processing time: 150 Days and 14.3 Hours
Core Tip
Core Tip: This review explores the complex interplay between inflammatory bowel disease (IBD) and metabolic dysfunction-associated steatotic liver disease, two increasingly prevalent conditions with shared key pathophysiological mechanisms. Chronic inflammation, gut dysbiosis, and intestinal barrier dysfunction are central to both diseases and interconnected through the gut–liver axis. Understanding this relationship highlights the importance of metabolic monitoring, lifestyle interventions, and early screening of hepatic and cardiovascular complications in patients with IBD.